Brokerages Set Repligen Corporation (NASDAQ:RGEN) Price Target at $166.43

Shares of Repligen Corporation (NASDAQ:RGEN) have received an average rating of “Buy” from the eighteen brokerages that are covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold recommendation, twelve have assigned a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $166.4286.

RGEN has been the subject of several recent analyst reports. Barclays raised their price objective on shares of Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Wolfe Research started coverage on Repligen in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price objective on the stock. Citigroup upgraded shares of Repligen to a “buy” rating in a report on Tuesday, July 7th. HSBC decreased their target price on shares of Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Finally, JPMorgan Chase & Co. lifted their target price on shares of Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $166.83 on Monday. The stock has a market cap of $9.42 billion, a PE ratio of 228.53, a price-to-earnings-growth ratio of 3.04 and a beta of 1.03. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. Repligen has a 52-week low of $100.99 and a 52-week high of $175.77. The business has a 50-day moving average price of $142.70 and a 200 day moving average price of $131.10.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.09. The firm had revenue of $204.13 million for the quarter, compared to the consensus estimate of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The firm’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.26 EPS. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities research analysts forecast that Repligen will post 2.06 earnings per share for the current year.

Insider Activity

In other news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the sale, the chief financial officer owned 19,359 shares in the company, valued at $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Repligen

Institutional investors have recently added to or reduced their stakes in the business. American Capital Management Inc. purchased a new position in Repligen during the second quarter worth about $49,262,000. Caisse de depot et placement du Quebec purchased a new stake in Repligen in the 2nd quarter valued at about $314,000. Jupiter Topco LLC purchased a new stake in Repligen in the 2nd quarter valued at about $55,393,000. ABS Investment Management LLC acquired a new position in shares of Repligen during the 2nd quarter valued at about $191,016,000. Finally, Hsbc Holdings PLC acquired a new position in shares of Repligen during the 2nd quarter valued at about $3,302,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.